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Rac2 Stimulates Akt Activation Affecting
BAD/Bcl-XL Expression while Mediating Survival
and Actin Function in Primary Mast Cells
proliferation, and gene transcription (Nobes and Hall,
1995; Hall, 1998; Westwick et al., 1997; Sanders et al.,
1999). The activities of the Rho GTPases are controlled
by extracellular signals that promote activation (GDP- to
GTP-bound states) via a number of guanine nucleotide
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1 Section of Hematology/Oncology exchange factors (GEFs) (Mackay and Hall, 1998). Rho
GTPases possess intrinsic GAP activity. There is evi-Herman B Wells Center for Pediatric Research
Department of Pediatrics dence that Rho GTPases, particularly Rho, Rac, and
Cdc42, may affect activation of each other in some cells2 Division of Hematology/Oncology
Department of Medicine (Burridge, 1999; Sanders et al., 1999).
Among the GTPases, Rac proteins have been shownWalther Oncology Center
Indiana University School of Medicine in fibroblasts to mediate de novo actin polymerization
at the cell periphery, leading to distinct actin filamentIndianapolis, Indiana 46202
3 Lilly Research Laboratories containing structures called lamellipodia extensions and
membrane ruffling (Nobes and Hall, 1995). This cellularIndianapolis, Indiana 46285
4 Howard Hughes Medical Institute structure has been implicated, particularly in fibroblasts,
in cell movement. Rac1 has been implicated in G1 cellIndiana University School of Medicine
Indianapolis, Indiana 46202 cycle progression (Olson et al., 1995; Lamarche et al.,
1996) and in Ras-mediated transformation in microinjec-
tion experiments utilizing dominant-negative and acti-
vated forms of the protein (Ridley et al., 1992; Qiu et al.,Summary
1995; White et al., 1995). Rac proteins have also been
shown to play a fundamental role in kinase signalingMast cells generated from Rac2-deficient (2/2) mice
pathways, leading to transcriptional activation of a vari-demonstrated defective actin-based functions, includ-
ety of genes (Vojtek and Cooper, 1995) and cell prolifera-ing adhesion, migration, and degranulation. Rac22/2
tion (Joneson and Bar-Sagi, 1998), and in superoxidemast cells generated lower numbers and less mast
generation in phagocytic cells via the NADPH oxidasecell colonies in response to growth factors and were
(Abo et al., 1991; Kreck et al., 1996). Rac and Cdc42deficient in vivo. Rac22/2 mast cells demonstrated a
have been shown in some cells to activate the amino-significant reduction in growth factor±induced sur-
terminal c-Jun kinase (JNK)/stress-activated protein ki-vival, which correlated with the lack of activation of
nase (SAPK) and p38 mitogen-activated protein kinaseAkt and significant changes in the expression of the
(MAPK) pathways (reviewed in Vojtek and Cooper, 1995),Bcl-2 family members BAD and Bcl-XL, in spite of a
while Rac also appears to be activated in some hemato-3-fold induction of Rac1 protein. These results suggest
poietic cells by phosphatidylinositol-3 kinase (PI-3K)that Rac2 plays a unique role in multiple cellular
(Nobes et al., 1995; Akasaki et al., 1999; Benard et al.,functions and describe an essential role for Rac2 in
1999).growth factor±dependent survival and expression of
Three members of the Rac family have been identified:BAD/Bcl-XL.
Rac1, Rac2, and Rac3. Rac1 and Rac2 share 92% se-
quence homology, and both are highly homologousIntroduction
(89%) to Rac3 (Didsbury et al.,1989). The major differ-
ence in these proteins is in the carboxy-terminal tail,The Rho GTPase family, members of the Ras superfam-
where Rac1 contains a stretch of basic amino acids,ily, controls organization of the actin cytoskeleton in all
whereas nonbasic residues in the Rac2 protein interrupteukaryotic cells (Haataja et al., 1997; Hall, 1998). Similar
this region. Unlike Rac1, which is ubiquitously ex-to other members of the Ras superfamily, Rho GTPases
pressed, Rac2 is expressed only in hematopoietic cellsfunction as molecular switches by cycling between
(Reibel et al., 1991). This restricted expression suggestsactive, GTP-bound and inactive, GDP-bound states
that Rac2 plays an important role in the specialized(Mackay and Hall, 1998). The mammalian Rho-like
functions of these cells. Using a genetic approach, weGTPases consist of several distinct proteins: Rho, Rac,
have recently shown that Rac2-deficient mice manifestCdc42, RhoD, RhoG, RhoE, and TC10 (Mackay and Hall,
defects in neutrophil chemotaxis, superoxide produc-1998). As demonstrated in fibroblasts and other nonhe-
tion, shear-dependent L-selectin-mediated capture onmatopoietic cells, in the active state, Rho GTPase pro-
the endothelial substrate Glycam-1, and F-actin genera-teins interact with a variety of effectors and play impor-
tion (Roberts et al., 1999). We (Williams et al., 2000)tant roles in diverse cellular functions, including actin
and Ambruso (Ambruso et al., 2000) have also recentlycytoskeletal organization, cell cycle progression and cell
described a dominant-negative Rac2 mutation associ-
ated with a similar phenotype in human. Since Rac15 To whom correspondence should be addressed (e-mail: dwilliam@
is also expressed in neutrophils, these genetic studiesiupui.edu).
suggest that Rac2 is a unique and nonredundant regula-6 Present address: Department of Protein Biochemistry, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406. tor of neutrophil functions. The function of Rac2 in other
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Figure 1. Expression of Rac 2 in Murine Mast
Cells
(A) RT-PCR analysis of Rac2 expression in
mast cells. RNA was purified from mast cells
of WT as well as Rac22/2 mice. cDNA derived
from 25 ng mRNA was used for PCR. Lane 1,
no reverse transcriptase; lane 2, Rac22/2
mast cells; lane 3, WT mast cells; lane 4, WT
neutrophils (positive control); PCR was per-
formed for 30 cycles.
(B) Immunoblot of mast cells derived from
Rac22/2 or WT mice probed for Rac2 protein
(upper panel) or Rac1 (middle pane); p38 was
used to demonstrate equal protein loading
(lower panel). Lane 1, mast cells from WT
mice; lane 2, mast cells from Rac22/2 mice;
lane 3, mast cells from Rac22/2 mice trans-
fected with Rac2 cDNA via retrovirus vector.
hematopoietic lineages remains to be elucidated. In ad- both the Rac2 RT-PCR product (Figure 1A, lane 2) and
detectable Rac2 protein (Figure 1B, lane 2). Unexpect-dition, since neutrophils are postmitotic cells, they may
not be optimal for examining the effects of Rac2 on cell edly, immunoblots of Rac22/2 cells consistently also
showed a 3-fold increase in the levels of Rac1 proteinproliferation and cell cycle progression.
Mast cells have been implicated in a variety of inflam- (Figure 1B, middle panel, lane 2), suggesting that Rac1
may be involved in compensatory pathways followingmatory conditions, including immediate hypersensitiv-
ity, and play an important role in host defense and innate the loss of the Rac2 gene product.
immunity (Galli and Wershil, 1996; Malaviya et al., 1996).
Bone marrow±derived mast cells provide an excellent Diminished Chemotaxis and Degranulation
primary cell system to investigate the role of Rac pro- of Rac22/2 Mast Cells
teins in regulating proliferation, survival, movement, and Our previous study (Roberts et al., 1999) implicated Rac2
degranulation. Here we show that the result of Rac2 in the regulation of actin-dependent cellular functions,
deficiency in mast cells in vivo is a decrease of mast such as chemotaxis, integrin-mediated cell spreading,
cell numbers in connective tissue of Rac22/2 mice. Fur- and phagocytosis. Therefore, we examined the effects
ther, we have generated homogenous primary bone of Rac2 deficiency on these functions in mast cells.
marrow±derived mast cell populations from Rac22/2 Chemotaxis was assessed using a transwell migration
mice and normal littermates. Utilizing these cells, we assay (Zou et al., 1998), in which cells in the upper
show that Rac2 plays an essential role in survival and chamber migrate through a membrane toward stem cell
growth of mast cells in addition to actin-based cellular factor (SCF) (Meininger et al., 1992) in the lower cham-
functions, including adhesion to fibronectin, movement, ber. Motility of mast cells was maximal when a gradient
and degranulation. We demonstrate that the deficien- was established using 10 ng/ml SCF in the lower cham-
cies in cell growth of Rac22/2 cells correlate with in- ber. Despite similar expression of the SCF receptor c-kit
creased apoptosis following growth factor stimulation, in both WT and Rac22/2 cells (Figure 2A, lower panel),
which at least in part appears to be a consequence of migration of Rac22/2 cells in response to SCF was signif-
defective activation of Akt. Defective Rac2 signaling is icantly reduced when compared with that of WT cells
also associated with increased expression of the Bcl-2 (Figure 2A, top panel) (5.4% versus 16%, respectively,
family proapoptotic protein BAD and decreased expres- at 10 ng/ml, p , 0.05).
sion of the Bcl-2 family antiapoptotic protein Bcl-XL. Cross-linking of the high-affinity receptor for IgE on
mast cells activates intracellular signaling pathways that
lead to degranulation and the subsequent release ofResults
serotonin (5-HT) and other preformed mediators of in-
flammation. The release of 5-HT can be further en-Rac1 and Rac2 Expression in Primary Murine
Mast Cells hanced by the addition of SCF (Coleman et al., 1993).
To determine if Rac2 is involved in the release of inflam-Although Rac2 has been shown to be expressed in sev-
eral cells of myeloid origin (Didsbury et al., 1989), expres- matory mediators by mast cells, we measured the re-
lease of [3H]-5HT from Rac22/2 versus WT mast cells.sion in various primary hematopoietic lineages has not
been described. To examine the expression of Rac2 As shown in Figure 2B (top panel), anti-IgE antibodies
or SCF 1 anti-IgE antibodies induced release of 5-HTmRNA and protein in wild-type (WT) mast cells, RT-PCR
and immunoblot analyses were performed. As shown in from the Rac2-deficient mast cells to a level significantly
lower than that induced in WT mast cells (2% versusFigure 1A, lane 3, the predicted 298 bp RT-PCR product
of Rac2 was obtained from WT mast cells. A representa- 12%, anti-IgE, and 4% versus 18%, anti-IgE 1 SCF,
respectively, p , 0.05). The diminished degranulationtive immunoblot is shown in Figure 1B, confirming the
expression of Rac2 protein in WT mast cells (lane 1). As induced by cross-linking of the IgER in Rac2-deficient
mast cells was not due to a difference in binding toexpected, mast cells derived from Rac22/2 mice lacked
Rac 2 Mediates Akt Activation and Cell Survival
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Figure 2. Function and Expression of c-kit, FceRI Receptor, and Integrins on Mast Cells
(A) Transwell analysis of mast cell chemotaxis in response to different doses of rrSCF (upper panel) and expression of c-kit on mast cells
(lower panel) after staining with an FITC-labeled anti-c-kit mAb (CD117, shaded area) or an isotype control IgG2b mAb (open area).
(B) Degranulation of mast cells measured by serotonin release stimulated by IgE receptor cross-linking after exposure or not to 200 ng/ml
SCF (upper panel). Data are the mean 6 SD of triplicates from representative experiments and are expressed as percentage of serotonin
release. Lower panel, FceRI expression analyzed by incubating cells with anti-DNP IgE, followed by staining cells with FITC-anti-IgE antibody.
(C) Expression of integrins CD49e and CD49d on WT mast cells (upper panel) or Rac22/2 mast cells (lower panel); mast cells were stained
with CD49d-FITC and biotin-conjugated CD49e followed by RPE-Cy5-conjugated streptavidin staining. Asterisk, p , 0.05.
FceRI (Figure 2B, bottom panel). These results demon- 13.1% 6 1%). Thus, the deficiency of Rac2 in mast cells
is associated with perturbations of adhesion via integrins,strate that Rac2 is essential for both the migration and
degranulation of bone marrow±derived mast cells. leading specifically to reduced adhesion via a5b1.
Rac22/2 Mast Cells Display Decreased ExpansionReduced Adhesion of Rac22/2 Mast Cells
to Fibronectin and Colony Formation In Vitro and Are
Decreased In VivoMast cells primarily reside and function in the extracellu-
lar space of many tissues (Dastych et al., 1991). There- Since Rac proteins have been implicated in cell cycle
progression and proliferation, we examined the growthfore, adhesive interactions between tissue mast cells
and the extracellular matrix are thought to play an impor- of mast cells derived from Rac22/2 mice in liquid cultures
and in colony assays. Mast cells were cultured in thetant role in migration, proliferation, and differentiation
and in the functional responses of mast cells. Murine presence of IL-3, SCF, or SCF 1 IL-3, and cell counts
were determined 3 days later. Expansion of Rac22/2mast cells adhere to the extracellular matrix protein FN
(Serve et al., 1995), and this adhesion is enhanced by cells in these cultures was significantly diminished rela-
tive to that of WT cells (Figure 3A) (45.5%, 54.3%, andstimulation with SCF (Dastych and Metcalfe, 1994). In
order to investigate the role of Rac2 in the adhesion of 47.1% of WT cell numbers, following culture with IL-3,
SCF, and SCF 1 IL-3, respectively). To determine if themast cells to FN, we examined SCF-stimulated binding
of these cells to recombinant FN peptides containing frequency or growth of mast cell progenitors were ab-
normal in mast cell populations derived from Rac22/2binding sites CS-1 or Arg-Gly-Asp-Ser, which are li-
gands for integrins a4b1 (CD49d) and a5b1 (CD49e), bone marrow, mast cells were also plated in a methylcel-
lulose colony assay. Compared with WT mice, mast cellsrespectively. Despite similar levels of surface expression
of CD49e and CD49d on WT and Rac22/2 mast cells derived from Rac22/2 mice produced a lower frequency
of mast cell colonies (Figure 3B). In addition, Rac22/2(Figure 2C), adhesion of Rac22/2 cells to RGDS con-
tained in the peptide CH271 was significantly reduced mast cell colonies uniformly failed to attain large sizes
in response to single cytokines or in response to bothrelative to that of WT cells (47.6% 6 4.8% versus
63.8% 6 5.6%, respectively, N 5 8, p , 0.05). Adhesion IL-3 and SCF (Figure 3B). Mast cells derived from hetero-
zygous mice demonstrated both normal growth in liquidof Rac22/2 mast cells to CS-1 contained in the peptide
H296 was slightly higher than WT cells, although this culture and normal colony sizes in these assays (data
not shown). The abnormalities in growth of mast cellsdifference was not significant (18.9% 6 3.7% versus
Immunity
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Figure 3. Expansion and Colony Formation of Mast Cells
(A) Fold expansion of mast cells in liquid cultures in response to mIL-3, rrSCF, or mIL-3 1 rrSCF. Cells were cultured for 3 days, then counted.
(B) Mast cell colony formation in the presence of different cytokines. The size of each colony was determined by visual inspection using an
inverted microscope, and in some cases this estimate was confirmed by counting the number of cells in colonies individually isolated. Colony
size was scored from large (four plus signs) to small (one plus sign). Asterisk, p , 0.05
ex vivo were associated with a modest but significant versus 7%; SCF, 33% versus 11%, Rac22/2 versus WT,
respectively). The largest difference was in the numberdecrease in mast cell numbers in vivo. Determination of
mast cell numbers in the skin of ear punch biopsies of early apoptotic cells, where a consistent 3- to 4-fold
increase in apoptosis was noted with either IL-3 or SCFshowed 10.4 6 1.6 versus 16.8 6 2.0 (Rac22/2 versus
WT, p 5 0.001) mast cells/high power field in biopsies stimulation (Figure 4B). These results suggest that defi-
ciency of Rac2 results in less growth factor±induced sur-stained with toluidine blue.
vival, indicating that the reduced expansion of Rac22/2
mast cells in vitro is due to increased apoptosis ratherDeficiency of Rac2 Is Associated with Decreased
than reduced proliferation by these cells.Growth Factor±Induced Survival
To determine whether the decreased expansion and
colony formation of Rac22/2 cells was due to reduced Rac2 Regulates Activation of Akt
In order to further evaluate the role of Rac2 in cytokine-DNA synthesis or increased cell death, cell cycling and
apoptosis of Rac22/2 and WT mast cells were measured. induced cell survival, we examined downstream signal-
ing pathways implicated in SCF/c-kit interactions in he-As shown in Figure 4A, propidium iodide (PI) staining of
cells after stimulation with IL-3 or SCF increased the matopoietic cells. Previous studies have demonstrated
that activation of PI-3K promotes cell survival by inhib-number of cells in S/G2/M compared with no growth
factor regardless of the genotype of the cells. There was iting apoptosis (Kulik et al., 1997) and that PI-3K is an
upstream effector of Akt (Burgering and Coffer, 1995;a slight but not significant reduction in the proportion
of Rac22/2 versus WT cells in the S/G2/M phase of the Franke et al., 1995; Klippel et al., 1996). In addition, Rac
proteins have been implicated in signaling via the PI-cell cycle after stimulation with SCF (27% Rac22/2 ver-
sus 33% WT), while no differences were noted after 3K pathway (Nobes et al., 1995; Akasaki et al., 1999;
Benard et al., 1999). PI-3K assays were performed tostimulation with IL-3. Since changes in cell growth were
observed with both IL-3 and SCF stimulation, these data determine if Rac22/2 mast cells were capable of activat-
ing PI-3K in response to SCF stimulation. Rac22/2 andsuggest that the changes in expansion and colony size
in Rac22/2 cells were not primarily associated with ab- WT mast cells were serum starved for 24 hr, then stimu-
lated with SCF and analyzed at various time points afternormalities of cell cycle progression.
We next investigated the survival of Rac22/2 cells after stimulation. As seen in Figure 5A, activation of PI-3K
was equivalent or slightly higher in Rac22/2 comparedgrowth factor stimulation. The percentage of early
(Annexin V1/PI2) and late (Annexin V1/PI1) apoptotic with WT cells. Figure 5B shows that the p85 protein
levels were slightly higher in Rac22/2 cells comparedcells in mast cell cultures was quantitated using flow
cytometry. Cells were cultured for 72 hr in the presence to WT, which correlated with the slightly higher PI-3K
induction seen on treatment of these cells with SCF.and absence of cytokines. As shown in Figure 4B, a
small increase in Rac22/2 apoptotic cell numbers com- Since Akt is a known target of PI-3K and has also been
implicated in the survival of several cell types, we nextpared with WT was noted in the absence of growth factor
stimulation. However, the number of dead or dying cells analyzed Akt activation after SCF stimulation. As seen
in Figure 5C, in spite of normal activation of PI-3K inwas increased 3- to 4-fold in Rac22/2 cells stimulated
with growth factors in comparison with WT (IL-3, 25% Rac22/2 mast cells, Akt activation was deficient in
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Figure 4. Analysis of Mast Cell Cycle and Cell Survival in Response to Growth Factor Stimulation
(A) Analysis of cell cycle by PI staining.
(B) Analysis of apoptosis and cell death by staining with PI and Annexin V. Mast cells were cultured with the indicated cytokines, and after
48 hr, cells were stained with PI and Annexin V as described in Experimental Procedures.
Rac22/2 mast cells after exposure to SCF throughout with protein 14-3-3 in the cytosol resulting in cell survival
the first 15 min posttreatment. In contrast, in WT mast through the actions of Bcl-2 and Bcl-XL. To clarify if Bad
cells, phosphorylation of Akt occurs and peaks at 15 is involved in a Rac2-dependent pathway promoting
min post-SCF stimulation (Figure 5C). The absence of survival in the presence of growth factors, we examined
Akt activation in response to SCF appeared specific the expression and phosphorylation of Bad in response
for Rac2 deficiency, since cells transfected with and to SCF. Phosphorylation of Bad increased after SCF
expressing WT Rac2 (Figure 1B, lane 3) showed restored stimulation in WT mast cells (Figure 6A, lanes 1±3). The
activation of Akt (Figure 5C, lanes 9±12, and see below). level of Bad phosphorylation appeared increased at
These data suggest that mast cells deficient in Rac2 baseline in Rac22/2 mast cells compared with WT cells,
undergo apoptosis in the presence of growth factor due but no obvious increase in Bad phosphorylation was
to defective activation of Akt even in the presence of seen in response to SCF at later time points examined
active PI-3K. To confirm the role of the PI-3K pathway (Figure 6A). In addition, unexpectedly, the level of total
in the increased apoptosis of Rac22/2 mast cells, apo- BAD protein available to bind Bcl-2 and Bcl-XL was in-
ptosis in WT mast cells was measured following stimula- creased z10-fold in Rac22/2 cells (Figure 6A, lanes 4±6).
tion with IL-3 or SCF in the presence of wortmannin. Increased levels of BAD protein were reduced some-
Addition of wortmannin to serum-starved, growth fac- what upon expression of WT Rac2 in transfected cells
tor-stimulated cells resulted in impaired phosphoryla- (Figure 6D, lanes 9±12). Furthermore, although the level
tion of Akt in the WT cells (data not shown), which was of Bcl-2 was not affected (Figure 6B), a significant reduc-
similar to that observed in Rac22/2 cells. Furthermore, tion in Bcl-XL protein was also demonstrated by immu-
addition of wortmannin to WT cells, cultured for 48 hr noblot (Figure 6C). Once again, this deficiency in Bcl-XL
in serum-depleted media in the presence and absence was reversed by expression of WT Rac2 in transfected
of cytokines resulted in a 3- to 5-fold increase in the cells (Figure 6C, lanes 9±12, and see below). In summary,
proportion of early and late apoptotic cells following the levels of proapoptotic BAD are significantly in-
stimulation with SCF (no growth factor, 2.9 6 0.3±fold creased while the levels of antiapoptotic Bcl-XL are sig-
increase in Annexin V1 cells and 1.8 6 0.4±fold increase nificantly decreased in Rac22/2 mast cells.
in AnnexinV1/PI1 cells; IL-3, 3.1 6 0.2±fold increase
in Annexin V1 cells and 5.0 6 1.0±fold increase in
The Cellular Defects in Rac22/2 Mast Cells Are DirectlyAnnexinV1/PI1 cells; SCF, 2.1 6 0.2±fold increase in
Related to Deficiency of Rac2 ProteinAnnexin V1 cells and 3.0 6 0.2±fold increase in An-
Generation of mast cell primary populations requiresnexinV1/PI1 cells; all values p , 0.05 versus untreated
culture for over 3 weeks in vitro. To confirm that thecontrols).
cellular phenotype observed in Rac22/2 cells was di-Bad, a downstream factor of Akt, is a proapoptotic
rectly related to Rac2 deficiency, we generated retroviralmember of the Bcl-2 family that can displace Bax from
vectors expressing the murine Rac2 cDNA (Figure 7A).binding to Bcl-2 and Bcl-XL, resulting in cell death (Yang
The MIEG3 vector has recently been described (Williamset al., 1996; Zha et al., 1996; Datta et al., 1997). Phos-
phorylation of Bad by Akt leads to sequestering of Bad et al., 2000) and is an improved vector backbone derived
Immunity
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Figure 5. Activation of PI-3K and Akt in WT
and Rac22/2 Mast Cells after Growth Factor
Stimulation
(A) Activation of PI-3K activity after stimula-
tion with SCF as determined by the in vitro
kinase activity of PI-3K immunoprecipitated
with a-PY antibody.
(B) Immunoblot using antibody to p85 regula-
tory subunit of PI-3K.
(C) Activation of Akt as determined by immu-
noblot of protein using a phospho-specific
anti-Akt antibody (upper panel). Lanes 9±12
show Akt activation in Rac22/2 cells express-
ing Rac2 after transduction using retroviral
vectors. Total protein shows p42/p44 MAPK
protein levels as a loading control.
from murine stem cell virus (MSCV) that expresses the 7C), which was not significantly different from WT cells.
Analysis of degranulation by serotonin release demon-enhanced green fluorescent protein (EGFP) via an inter-
nal ribosome reentry site (IRES). The murine Rac2 cDNA strated that transfected Rac22/2 mast cells expressing
Rac2 cDNA degranulated significantly more than uncor-was inserted upstream of the IRES element, allowing
bicistronic expression of both Rac2 and EGFP. Rac22/2 rected cells in a fashion quantitatively similar to WT cells
(Figure 7D). The observed corrected degranulation ofcells were infected with either the vector control (MIEG3,
containing only the EGFP protein) or MIEG3-FR2 (con- Rac22/2 mast cells represented 80% of WT levels. Fi-
nally, consistent with the corrections in other cellulartaining the WT Rac2 cDNA) and then examined for
expansion, cloning efficiency, degranulation, and migra- phenotypes, transfected Rac22/2 cells expressing WT
Rac2 demonstrated correction of the defect in Akt phos-tion. Expression of Rac2 was confirmed by immunoblot
(Figure 1B, lane 3). Expansion of Rac22/2 cells trans- phorylation after stimulation with SCF (Figure 5C, lanes
9±12), increased expression of Bcl-XL (Figure 6C, lanesfected with either WT Rac2 (MIEG3-FR2) or vector con-
trol (MIEG3) was assessed by flow cytometric analysis 9±12), and reduced expression of BAD (Figure 6D,
lanes 9±12).of the proportion of cells expressing the EGFP reporter
gene. As shown in Figure 7B (inset), the proportion of
EGFP1 cells in cultures transfected with MIEG3-FR2 Discussion
increased over a period of 8.5 weeks, from 0.4% to 10%,
whereas the proportion of EGFP1 cells transfected with Phagocytic cells of the blood must respond to chemo-
tactic gradients, engulf microorganisms, and generateMIEG3 alone remained the same. Methylcellulose col-
ony assay of these cells shows that transfection of WT oxidants to destroy phagocytized bacteria. Based pri-
marily on studies that have relied upon introduction ofRac2 completely rescued not only the total frequency of
clonogenic cells, but also their colony size, as compared dominant-negative or activated forms of these GTPases
into cell lines, Rho GTPases appear to effect cytoskele-with WT cells (Figure 7B). Migration of Rac22/2 mast
cells toward SCF was corrected to 75% of WT levels tal and biochemical changes required for all these func-
tions (Waddell et al., 1995; Cox et al., 1997; Jonesonafter by expression of WT Rac2 in Rac22/2 cells (Figure
Rac 2 Mediates Akt Activation and Cell Survival
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Figure 6. Activation and Expression of Bad
in WT and Rac22/2 Mast Cells
(A) Activation of Bad after SCF stimulation
was determined using immunoblot with phos-
pho-specific antibody (upper panel) and total
Bad protein determined by immunoblot
(lower panel).
(B) Expression of Bcl-2 protein in WT and
Rac22/2 mast cells determined by immu-
noblot.
(C) Expression of Bcl-XL in WT and Rac22/2
mast cells determined by immunoblot. Lanes
9±12 show expression of Bcl-XL in Rac22/2
mast cells expressing Rac2 after transduc-
tion using retrovirus vectors.
(D) Expression of BAD in WT and Rac22/2
mast cells expressing Rac2 after transfection
using retrovirus vectors.
Bar-Sagi, 1998). In addition, Rho GTPase proteins of understood. Previous studies noted increased expres-
sion of Rac protein (presumably Rac1) in gelsolin-defi-the Rac family are increasingly recognized as signaling
molecules involved in T lymphocyte development and cient mice (Azuma et al., 1998). Data presented here
show increased expression of Rac1 protein in Rac22/2activation (Lores et al., 1997; Turner et al., 1997; Li et
al., 2000). The role of these proteins in differentiation cells. Taken together, these data suggest some addi-
tional feedback regulation of Rac GTPase expression.and function of other hematopoietic cells that mediate
immune functions has been less well characterized. In Rac2 differs from Rac1 by the interruption of a six car-
boxy-terminal basic amino acid stretch with two gluta-this study, we used a genetic approach to demonstrate
that Rac2 plays an important role in actin-based cellular mine residues. The data presented here, along with our
previous study examining neutrophil function in Rac2-functions in primary murine mast cells. Not unexpect-
edly, deficiencies in actin-based functions are a result of deficient cells, suggest that in spite of a high degree of
sequence homology, Rac2 plays an unique and nonre-gene deletion and are reversed by expression of normal
Rac2 protein using retroviral-mediated gene transfer. dundant role in hematopoietic cell function, which is not
rescued by increased Rac1 protein expression. SinceWhile Rac1 and Rac2 are highly homologous and are
both expressed in hematopoietic cells, the expression some GEFs and effectors are specific for certain
GTPases (Diekmann et al., 1995; reviewed in Van Aelstof Rac2 is hematopoietic specific (Didsbury et al., 1989;
Shirsat et al., 1990; Moll et al., 1991; Haataja et al., 1997). and D'Souza-Schorey, 1997), while others act on most
or all members of the family, these data suggest thatThe regulation of this lineage-specific expression is not
Immunity
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Figure 7. Effect of Expression of Rac2 in Mast Cells after Transduction with Retrovirus Vectors Expressing Rac2
(A) Retroviral vectors MIEG3 and MIEG3-FR2 (see Experimental Procedures).
(B) Growth and colony formation of Rac2-transduced cells. Inset growth of GFP1 cells in Rac22/2 cell population over 8 weeks after infection
(solid circles, Rac2 expressing; open circles, cells expressing only GFP); both the number and size of mast cell colonies are rescued by
expression of Rac2 compared to mock-transduced or cells expressing GFP only (vector control). Size of colonies estimated as in Figure 3.
Asterisk, p , 0.05 Rac2 transfected and WT versus mock and vector control (number of colonies).
(C) Chemotaxis and (D) degranulation of Rac22/2 mast cells after transfection with MIEG3-FR2. Transduced and GFP1 cells were sorted to
purity prior to assays in (C) and (D).
this same level of specificity might apply to individual transcription, cell cycle progression, activation of intra-
cellular signaling pathways, and Ras-mediated transfor-members of each GTPase family (i.e., Rac1 versus
Rac2). Specificity is particularly noteworthy in Rac acti- mation (Nobes and Hall, 1995; Olson et al., 1995; La-
marche et al., 1996; Westwick et al., 1997; Hall, 1998).vation of the NADPH oxidase, where deficiency in super-
oxide generation in neutrophils of Rac2-deficient mice is The exact role of GTPases in these processes remains
incompletely understood. Rac and Cdc42 have pre-agonist specific (Roberts et al., 1999; C. K. and M. C. D.,
unpublished data). Alternatively, since signaling mole- viously been reported to activate JNK (SAPK) and p38
MAPK pathways (Vojtek and Der, 1998) and show se-cules with polybasic regions may colocalize within re-
gions of the plasma membrane enriched in acidic phos- quence homology to Drosophila (Glise and Noselli, 1997)
and S. cerevisiae (Leberer et al., 1997) genes related topholipids, differences seen between Rac1 and Rac2 may
relate to relative concentrations of critical molecules at both of these mammalian signaling pathways. In neutro-
phils lacking Rac2, we have demonstrated deficiencyspecific subcellular locales. To date, few effectors of
Rac have been identified so that the complexity of regu- in fMLP-induced activation of p38 and p42/p44 MAPK
(Roberts et al., 1999) and several groups have implicatedlation of cellular function is likely to grow as new candi-
date proteins are examined with respect to interaction PI-3K in the activation of Rac after fMLP stimulation
(Nobes et al., 1995; Akasaki et al., 1999; Benard et al.,with specific Rac family members (Diekmann et al.,
1995;Vojtek and Der, 1998). 1999). Using expression of dominant-negative Rac1,
previous studies utilizing mast cells have implicated RacActivated GTPases have also been implicated in gene
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family proteins in response of cells to growth factor downstream effects on the Bcl-2 family of proteins con-
stimulation (O'Sullivan et al., 1996), and O'Sullivan et trolling cell survival and cell death. These defects, along
al. have also demonstrated that Rac complexed with with the abnormalities in actin-based cell function de-
GOAD-II (a RhoGDI) can inhibit degranulation in perme- scribed here further suggest that Rac2 mediates specific
abilized mast cells. Here we demonstrate that Rac2 is cellular events in hematopoietic cells that are unique
essential for activation of Akt after SCF stimulation. Loss compared with other Rac proteins. The Rac2 se-
of Akt activation in response to growth factor stimulation quences, which are critical to the specificity of these
of a receptor tyrosine kinase is associated with reduced cellular functions and the effector molecules regulating
cell survival. The increase in apoptosis seen in Rac22/2 Rac2 activity in mast cells, are currently being delin-
mast cells is consistent with the known important of role eated.
of Akt in mediating cell survival and downregulation of
Experimental Procedurescell death signals (Zha et al., 1996; Ahmed et al., 1997;
Datta et al., 1997; del Peso et al., 1997; Kennedy et al.,
Materials and Cell Preparations1997). Previously, Nishida et al. (1999) have implicated
Chemicals were purchased from Sigma (St. Louis, MO) unless other-
Rac in preventing apoptosis in BaF3 cell lines. Changes wise stated.
in Akt activation appear to be the direct result of deficient Rac2-deficient (Rac22/2) mice and their normal littermates have
Rac2 signaling, since expression of Rac2 from a retrovi- been described previously (Roberts et al., 1999). Bone marrow±
derived mast cells were generated by culturing bone marrow cellsrus vector introduced into Rac22/2 cells restores both
in RPMI 1640 (Life Technologies, Rockville, MD) supplemented withAkt signaling and cell growth to normal levels. Impor-
10% fetal bovine serum (FBS, HyClone, Logan, UT), 100 U/ml oftantly, data presented here clearly demonstrate that
penicillin and 100 mg/ml of streptomycin, 2 mM of glutamine (Life
Rac2 functions downstream or at least in parallel of PI- Technologies), and recombinant murine interleukin-3 (mIL-3, 10 ng/
3K and upstream of Akt. ml, PeproTech, Rocky Hill, NJ) (complete RPMI) for 5 weeks.
The loss of Rac2 expression in mast cells is associ-
Construction of Retroviral Vectors and Infection of Mast Cellsated with significant changes in the protein levels of two
An improved MSCV-based bicistronic retroviral vector, MIEG3-major proteins of the Bcl-2 family of proteins, which are
expressing enhanced green fluorescence protein (EGFP), was con-comprised of both positive and negative regulators of
structed as previously described (Williams et al., 2000) and containscell death (Zha et al., 1996; Datta et al., 1997). Previous the encephalomyocarditis virus (EMCV) IRES element in its original
studies have demonstrated Akt phosphorylation of BAD EMCV viral configuration resulting in more efficient translation of
leads to increased cell survival (Datta et al., 1997). Rac2- EGFP. The Flag epitope tag was introduced into the N-terminal
region of the murine wild-type Rac2 cDNA using a PCR-based tech-deficient mast cells express significantly more BAD pro-
nique. The primers used in this study were as follows: 59-CCGGAATtein, which exerts death-promoting effects by hetero-
TCACCATGGACTACAAAGACGATGACGACAAGCAGGCCATCAAGdimerization with Bcl-2 or Bcl-XL, and significantly less
TGTGTGGTGGTGGGTGATG-39 and 59-CCGCTCGAGCCTAGAGBcl-XL protein, which exerts survival-promoting effects CAGGCTGCAGGGGCGCTTCTGCTG-39. The amplified fragments
after release from BAD (Zha et al., 1996; Datta et al., were cloned into pPCR-script SK plasmid (Stratagene) and se-
1997). In Rac22/2 mast cells, phosphorylated BAD, quenced. The sequence-confirmed Flag-tagged Rac2 was digested
which has been shown to be sequestered with 14-3-3 with EcoRI and XhoI and cloned into the same sites of MIEG3,
yielding MIEG3FR2 vector.protein and therefore not available to neutralize the anti-
Viral supernatant collected 48±72 hr after transfection of Phoenix-apoptotic effects of Bcl-2 and Bcl-XL, remains relatively
Ampho cell (obtained from American Type Culture Collection, Man-unaffected. The net result of these changes appears to
assas, VA) were used to infect the GP 1 E86 packaging cell linebe a large increase in the proapoptotic function of BAD
(Markowitz et al., 1988). The GFP-expressing cells with high fluores-
concomitant with a decrease in the amount of Bcl-XL cent intensity were established as stable producer cells. The retrovi-
available to prevent cell death. These changes may con- ral titer was determined by FACS analysis using a method previously
tribute to the resultant increase in cell death seen in reported (Felts et al., 1999). The titers of MIEG3 or MIEG3FR2 viral
supernatant were 2.5 3 104 and 1.4 3 105 CFU/ml, respectively. TheRac2-deficient mast cells. Restoration of Rac2 activity
retroviral supernatant was used to infect Rac22/2 mast cells usingin mast cells does lead to normal or even elevated levels
the procedures described previously with minor modifications (Pol-of Bcl-XL protein, which suggests a primary effect of lok et al., 1998). The infected cells were analyzed for GFP expressionRac2. Previous studies have demonstrated regulation using a FACScan (Becton Dickinson, Mountain View, CA) 48 hr fol-
of Bcl-XL expression in several hematopoietic lineages lowing the infection.
(Dibbert et al., 1998; Gregory et al., 1999; Kuribara et
al., 1999; Oritani et al., 1999; Sevilla et al., 1999; Wein- Reverse Transcription-PCR and Immunoblot Analysis
RT-PCR was performed to examine mRNA expression of Rac2 inmann et al., 1999), possibly via GATA or Ets2 transcrip-
WT mast cells and Rac2 knockout mast cells, using oligonucleotidetion factors (Gregory et al., 1999; Sevilla et al., 1999).
primers for Rac2: sense, 59-TGAGAATGTCCGTGCCAAGTGG-39;Modulation of expression of BAD has not been pre-
antisense, 59-CTTCTGCTGTCGTGTGGGCTGT-39; and b-actin (as a
viously reported in hematopoietic cells, although Mok positive control): upstream, 59-GTGGGCCGCTCTAGGCACCAA-39;
et al. recently reported upregulation of BAD expression downstream, 59-CTCTTTGATGTCACGCACGATTTC-39. RNA was
during thymocyte apoptosis (Mok et al., 1999). isolated from mast cells using QuickPrep Micro mRNA purification
The studies presented here further clarify the role of kit (Amersham Pharmacia Biotech, Piscataway, NJ). Murine leuke-
mia virus reverse transcriptase (Perkin Elmer, Roche, Indianapolis,Rac proteins in both cell movement, adhesion and cell
IN) and the 39 oligonucleotide complementing nucleotides 539±557survival. Surprisingly, Rac2-deficient mast cells appear
were used for first strand cDNA synthesis from 25 ng mRNA isolatedto progress through G1 without difficulty, although an
from mast cells. PCR conditions were 30 cycles (948C for 60 s, 558C
increased number of mast cells subsequently undergo for 30 s, and 728C for 60 s) using a DNA thermocycler (Programmable
programmed cell death in response to growth factor Thermal Controller, MJ Research, Waltham, MA). Immunoblot analy-
stimulation. We demonstrate that this cell death is likely sis was performed as previously described (Roberts et al., 1999)
using the following reagents: polyclonal rabbit antiserum raisedto be a consequence of defective Akt activation and
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against recombinant human Rac2 (1:5000 dilution; kindly provided PBS. Tritiated counts per minutes in supernatant and pellet fractions
were determined by scintillation counting in Hydroflour (Fisherby G. Bokoch) and a monoclonal anti-Rac1 antibody (1:5000 dilution;
clone 23A8, Upstate Biotechnology, Waltham, MA). Chemicals, NJ), and the percentage of serotonin release was calcu-
lated as [(a 2 b) / c] 3 100, where a is serotonin released by stimu-
lated cells, b is that of unstimulated cells, and c is the total incorpo-Proliferation and Colony Formation in Response
rated cellular serotonin.to Growth Factors
Mast cell proliferation assays were performed as previously de-
Analysis of Integrin, Kit, and Fce RI Receptor Expressionscribed (Meininger et al., 1992). Cells were cultured in triplicate at
Antibodies for flow cytometry were purchased from PharMingen.1 3 105 cells/ml in 24-well plates containing complete RPMI, in the
Mast cells were incubated with fluorescein isothiocyanate (FITC)presence or absence of cytokines [10 ng/ml of mIL-3, 100 ng/ml of
anti-mouse CD117 (c-kit) or FITC anti-mouse CD49d (a4b1 integrin)recombinant rat (rr) stem cell factor (SCF) (Amgen, Thousand Oaks,
or biotinylated anti-mouse CD49e (a5b1 integrin) for 30 min at 48C.CA), or mIL-3 1 SCF]. After incubation for 72 hr at 378C and 5%
After washing cells twice with PBS, RPE-Cy5-conjugated streptavi-CO2, the cells were harvested and counted with a hemocytometer,
din was add to biotinylated anti-mouse CD49e. Flow cytometricand the data are presented as fold increase of cell numbers com-
analysis was performed using a FACScan. FceRI receptor densitypared with the starting cell number. To examine the colony-forming
was measured according to the method of Hsu and MacGlashancapacity of mast cells, clonal cell cultures were done in triplicate,
(1996); mast cells (2 3 106 cells/ml) were incubated with anti-DNPas described previously (Nakahata and Ogawa, 1982). Colonies were
IgE at 378C for 30 min in complete RPMI; the cells were subsequentlydetermined on day 14 of incubation by in situ observation using an
incubated with 10 mg/ml of FITC-conjugated anti-mouse IgE (Phar-inverted microscope. Colony sizes were scored visually and verified
Mingen) for 30 min on ice. Controls included staining cells not pre-by picking individual colonies and counting using a hemocytometer.
treated with IgE. Mean fluorescence values were measured using
flow cytometry gated based on forward and side scatter and ex-Determination of Cell Cycle and Apoptosis
cluded debris.Mast cells were cultured in the presence or absence of different
cytokines at 2 3 105/ml in complete RPMI. Cell cycle analysis was
Intracellular Signaling Pathwaysperformed after 48 hr by staining with equal volumes of 2 mg/ml
Wild-type and Rac22/2 mast cells in RPMI (2 3 106/ml) were stimu-RNase A in PBS and 0.6% NP40 containing 0.1 mg/ml propidium
lated with 10 ng SCF/ml for the indicated times. Cells were lysediodide (PI; Calbiochem, La Jolla, CA) in PBS at 48C for 30 min.
in lysis buffer containing 10 mM K2HPO4, 1 mM EDTA, 5 mM EGTA,Thereafter, cell cycle distribution was analyzed by flow cytometry
10 mM MgCl2, 1 mM Na3VO4, 50 mM sodium b-glycerophosphate,as previously described (Aguiar et al., 1999). For apoptosis assays,
10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mg/ml pepstatin A (pHcells were harvested and resuspended in 100 ml of binding buffer
7.2). Lysates were clarified by centrifugation at 10,000 3 g, 48C for(10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 2.5 mM CaCl2). Cells
30 min. Immunoblot analyses of Akt and Bad phosphorylation levelswere then stained with 5 ml of AnnexinV-FITC (PharMingen, San
were carried out using phospho-specific antibodies, according toDiego, CA) and 500 ng of PI, incubated at room temperature for 15
manufacturer's instructions (New England Biolabs, Beverly, MA).min in the dark and analyzed by flow cytometric analysis using a
PI-3K assays were performed on lysate protein (500 mg) from wild-FACScan flow cytometer (Becton Dickinson).
type and Rac22/2 mast cells, which had been stimulated for 0, 1, 5,
or 10 min with 10 ng/ml SCF. Assays were carried out essentiallyMigration and Cell Adhesion Assays
as per the protocol given by Upstate Biotechnology, using the PY99Migration of mast cells was evaluated using a transwell migration
antiphosphotyrosine mAb (Santa Cruz, Santa Cruz, CA) with minorassay (Zou et al., 1998). Briefly, 5 3 105 mast cells in 100 ml of
modifications (Whitman et al., 1985). PI-3K p85 subunit levels inserum-free chemotaxis buffer (RPMI 1640, 0.5% BSA) were loaded
lysate protein (15 mg) were compared by immunoblot analysis usingonto each transwell filter (8 mm pore filter transwell, 24-well cell
anti-p85a antibody (Upstate Biotechnology).clusters; Costar, Boston, MA). Filters were then placed in wells
containing 600 ml of serum-free chemotaxis buffer supplemented
Statistical Analysiswith varing concentrations of rrSCF (as indicated). After 4 hr incuba-
All experiments were performed at least twice. The data are ex-tion at 378C in 5% CO2, the upper chamber was carefully removed,
pressed as the mean 6 SD of triplicate plates in colony formation.and the cells in the bottom chamber were resuspended and counted
Student's t test was used to determine the statistical significance.using a hemacytometer. All assays were performed in triplicates.
Adhesion of mast cells was assayed described (van der Loo et
Acknowledgmentsal., 1998). Briefly, nontissue culture plates were coated with FN
fragments (H-296, which contains the a4b1 binding site; CH-271,
We thank Eva Meunier and Sharon Smoot for assistance in prepara-which contains the a5b1 binding site) at 8 mg/cm2 or BSA (as control)
tion of this manuscript. This work is supported by NIH R01 DK48605over night at 48C, followed by blocking with 2% BSA in PBS. WT or
(D. A. W.) and NIH R01 HL-45635 (M. C. D.). We thank Dr. StanRac22/2 mast cells in RPMI (2 3 106/ml) containing 10% FBS in the
Korsmeyer for useful discussions.presence of 10 ng/ml SCF were then allowed to adhere to the coated
plates for 1 hr at 378C. After incubation, nonadherent cells were
collected by carefully rinsing the plates multiple times with medium. References
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